Advances in the understanding of diabetes mellitus

Drug News and Perspectives

Volumn 17, Issue 7, 2004, Pages 477-487

  Bandyopadhyay, Prabirkumar ^a,b  

^a Diabetes and Endocrinolgy ^*  (United Kingdom)

^b SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; APOLIPOPROTEIN B; ASCORBIC ACID; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; EXENDIN 4; FIBRIC ACID DERIVATIVE; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; MURAGLITAZAR; NAVEGLITAZAR; ORAL ANTIDIABETIC AGENT; PEPTIDE HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PPARPAN; PRAMLINTIDE; R 483; RAPAMYCIN; ROSIGLITAZONE; SITAGLIPTIN; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; T 0903131; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ALTERNATIVE MEDICINE; ATHEROSCLEROSIS; BARIATRIC SURGERY; BLOOD GLUCOSE MONITORING; CARDIOMEGALY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; EDEMA; EPIDEMIOLOGICAL DATA; ETHNIC DIFFERENCE; EXERCISE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SURVEY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET TRANSPLANTATION; PATHOGENESIS; PATIENT CARE; PREVENTION; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

DIABETES MELLITUS; GENE THERAPY; HUMANS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS TRANSPLANTATION; PREVALENCE;

EID: 6344250464     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. The Search for Diabetes in Youth Study Group. Diabetes in 0-19 year old youth in the U.S.: Higher than expected incidence rates. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 200-OR.
2. Imperatore, G., Cheng, Y., Williams, D.E. and Gregg, E.W. Physical activity and insulin sensitivity among US adolescents: The National Health and Nutrition Examination Survey 1999-2000. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 199-OR.
3. Pilot Feasibility Study Group of the Studies to Treat or Prevent Type 2 Diabetes Collaborative Group. Obesity, diabetes and the metabolic syndrome in 8th grade children. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 29-OR.
4. Monzavi, R., Dreimane, D., Geffner, M. et al. Improvement in metabolic syndrome and insulin resistance in obese youth treated with lifestyle intervention. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 30-OR.
5. Steck, A.K., Barriga, K.J., Emery, L.M. et al. Secondary attack rate of type 1 diabetes in Colorado families, 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 195-OR.
6. Libman, I.L., Pietropaolo, M., Laporte, R.E. et al. Black/white differences in progressors to insulin-treated diabetes in first degree relatives of children with insulin requiring diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 196-OR.
7. Shankar, A., Wong, T., Klein, B. and Klein, R. Retinal arteriolar narrowing and incident diabetes mellitus. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 279-OR.
8. Jehn, M.I. and Guallar, E. Serum ferritin and risk of metabolic syndrome in US adults: The Third National Health and Nutrition Examination Survey. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 281-OR.
9. Schulze, M.B., Willett, W.C. Manson, J.E. et al. Consumption of sugar-sweetened soft drinks is related to greater weight gain and increased risk of type 2 diabetes in women. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 282-OR.
10. Yeh, H.-C, Schmidt, M.I., Duncan, B.B. and Brancati, F.I. Smoking and the risk of incident type 2 diabetes mellitus. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 283-OR.
11. Grill, V., Carlsson, S. and Midthjell, K. Smoking is associated with an increased risk of type 2 diabetes but a decreased risk of autoimmune diabetes: An 11 year follow-up of Incidence of Diabetes in the Nord-Trøndelag Study. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 286-OR.
12. Hanley, A.J., Williams, K., Wagenknecht, L.E. et al. Elevations in markers of liver injury and risk of type 2 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 284-OR.
13. Duncan, B.B., Schmidt, M.I., Pankow, J.S. et al. Adiponectin and the development of type 2 diabetes mellitus - The ARIC Study. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 285-OR.
14. Musen, G., Lyoo, I.K., Sparks, C. et al. Evidence for reduced gray matter density in patients with type 1 diabetes as measured by magnetic resonance imaging. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 247-OR.
15. Stratton, I.M., Boulton, A. and Holman, R.R. Prevalence, incidence and risk factors for neuropathy in type 2 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 246-OR.
16. Young, B.A., Katon, W., Simon, G. et al. Ethnic differences in microalbuminuria prevalence in a diabetes population: The Pathways Study. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 242-OR.
17. Penno, G., Pucci, L., Lucchesi, D. et al. Insulin resistance and microvascular complications in type I diabetes: The Italian cohort of the EURODIAB Prospective Complications Study. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 243-OR.
18. Sivitz, W., Bautista, O., Cleary, P.A. et al. Skin collagen glycation products predict the progression risk of diabetic retinopathy and nephropathy in the Epidemiology of Diabetes and Intensive Control Study. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 248-OR.
19. Befroy, D.B., Petersen, K.F., Dufour, S. and Shulman, G.I. Impaired mitochondrial oxidation in insulin resistant offspring of type 2 diabetics. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 84-OR.
20. Tonelli, J., Kishore, P., Weaver, C. and Hawkins, M. Effects of free fatty acids on pai-1 levels do not rapidly reverse in type 2 diabetes mellitus. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 117-OR.
21. Saely, C.H., Aczel, S., Marte, T. et al. The metabolic syndrome is independently and gradually predictive for vascular events both in diabetic and in non-diabetic coronary patients. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 118-OR.
22. Cull, C.A., Jensen, C.C. and Holman, R.R. Metabolic syndrome is associated with an increased risk of the macrovascular but not microvascular complications of type 2 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 120-OR.
23. Pladevall, M., Lafata, J.E., Simpkins, J. et al. Trends in the management of dyslipidemia in patients with diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 948-P.
24. Cziraky, M.J., Willey, V.J., Bullano, M.F. et al. Assessment of combined lipid goal attainment in 8,855 diabetic patients. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 930-P.
25. Wadwa, R.P., Maahs, D.M., Kinney, G.I. et al. Dyslipidemia in type 1 diabetes mellitus: Awareness, treatment and control in the CACTI Study. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 949-P.
26. Leiter, L.A., Betteridge, F.J. and the Audit Investigators. The AUDIT Study: A worldwide survey of physician attitudes about diabetic dyslipidemia. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 1170-P.
27. Bolli, G.B., Capani, C., Home, P.D. et al. Comparison of a multiple daily injection regimen with once-daily insulin glargine basal insulin and mealtime lispro, to continuous subcutaneous insulin infusion: A randomised, open, parallel study. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 455-P.
28. Kern, W., Benedict, C., Hallschmid, M. et al. Intranasal insulin improves memory in man. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 106-OR.
29. Frost, C.E., Swaminathan, A., Raymond, R. et al. Lipid lowering effects of multiple dose administration of muraglitazar (BMS-298585), a novel PPAR alpha/gamma dual agonist, in type 2 diabetic patients. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 1988-PO.
30. Mosqueda-Garcia, R., Frost, C.E., Swaminathan, A. et al. Glucose lowering effects of multiple dose administration of muraglitazar (BMS-298585), a novel PPAR alpha/gamma dual agonist, in type 2 diabetic patients. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 138-OR.
31. Harrity, H., Chu, C., Kunselman, L. et al. Muraglitazar, a novel non-TZD dual PPAR alpha/gamma agonist, improves metabolic abnormalities in obese, severely diabetic db/db mice. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 134-OR.
32. Konrad, K., Luebben, G. and Franzen, C. Pioglitazone lowers blood pressure in hypertensive patients with type-2-diabetes mellitus. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 658-P.
33. Konrad, K., Fuellert, S. and Luebben, G.. Pioglitazone improves fasting and post-challenge indices of insulin resistance in obese patients with essential hypertension. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 657-P.
34. Pampanelli, S., Rinaldi, T., Perriello, G. and Brunetti, P. Effects of pioglitazone on coagulation and thrombosis in comparison to gliclazide in patients with type 2 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 589-P.
35. Khanolkar, M., Thomas, A., Singh, N. et al. Effects of rosiglitazone on platelet aggregation. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 556-P.
36. Weber, C., Kuhn, B. and Fotteler, B. R483, a Novel thiazolidinedione, improves glycemia and is well tolerated in healthy subjects and patients with type 2 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 2028-PO.
37. Kersey, K., Floren, L.C., Pendleton, B. et al. T0903131, a selective modulator of PPAR-gamma activity, increases adiponectin levels in healthy subjects. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 656-P.
38. Prince, M., Spicer, K., Caro, J. et al. Efficacy of LY519818, a novel non-TZD, PPARgamma-dominant alpha/gamma dual agonist. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 139-OR.
39. Dardik, B., Stevens, D., Schwartzkopf, C. et al. Effects of a dual PPARalpha/gamma agonist on lipid metabolism and cardiovascular risk factors in obese cynomolgus monkeys and normal dogs. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 931-P.
40. Lewis, M.C., Wilson, J.G., Ignar, D.M. and Oliver, W.R., Jr. The effects of PPARalpha, delta and PPARpan™ agonists on diet-induced obesity in fat-fed AKR mice. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 565-P.
41. Ortmeyer, H.K., Collins, C.A., Minnick, D.T. et al. PPARpan™ agonist treatment improves lipid utilization via tissue-specific effects on skeletal muscle and adipose tissue lipoprotein lipase activity in obese monkeys. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 666-P.
42. Defronzo, R., Ratner, R., Han, J. et al. Effects of Exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 6-LB.
43. Kendall, D.M., Riddle, M.C., Zhuang, D. et al. Effects of exenatide (exendin-4) on glycemic control and weight in patients with type 2 diabetes treated with metformin and a sulfonylurea. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 10-LB.
44. Ceriello, A., Frias, J., Wang, Y. et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 349-OR.
45. Chapman, I., Parker, B., Doran, S. et al. Effect of Pramlintide on ad-libitum food intake in obese subjects and subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over study. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 350-OR.
46. Ahren, B., Gomis, R., Mills, D. and Schweizer, A. Patients with type 2 diabetes inadequately treated with metformin. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 354-OR.
47. Pratley, R. and Galbreath, E. Twelve-week monotherapy with the DPP-4 Inhibitor, LAF237 improves glycemic control in patients with type 2 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 355-OR.
48. Herman, G.A., Zhao, P.-L., Dietrich, B. et al. The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 353-OR.
49. Shapiro, J., Ricordi, C., Hering, B. et al. International multi-center trial of islet transplantation using the Edmonton protocol in patients with type 1 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 1904-P.
50. Galassetti, P., Nemet, D., Rose-Gottron, C. et al. Exhaled volatile organic compounds: Potential non-invasive markers of plasma glucose during an oral glucose tolerance test. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 435-P.
51. Ghevondian, N., Nguyen, H. and Colagiuri, S. The HypoMon®: A novel non-invasive hypoglycemia monitor using machine intelligence. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 437-P.
52. Martin, C.I., Cleary, P.A., Greene, D.A. et al. Persistent effects of intensive therapy eight years after the Diabetes Control and Complications Trial. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 244-OR.
53. De Filippis, E.A., Cusi, K., Fernandez, M. and Mandarino, L.J. Exercise improves endothelial function in type 2 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 32-OR.
54. Yokoyama, H., Emoto, M., Araki, T. et al. Short-term aerobic exercise improves arterial stiffness in type 2 diabetes. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 33-OR.
55. Kurian, R.T., Barve, S.S., Ritchie, C.S. et al. Resistance training improves neurological function and cardiovascular risk factors in elderly subjects with type 2 diabetes mellitus and peripheral neuropathic symptoms. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 34-OR.
56. Short, O.K., Short, K.R., Joyner, M.J. et al. The effect of chronic exercise training on age-related changes in insulin sensitivity, muscle fiber type, and mitochondrial ATP production. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 36-OR.
57. Goodpaster, B.H., Menchikova, E.V., Fairfull, L. et al. Exercise increases skeletal muscle mitochondria content of older adults. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 37-OR.
58. Karne, R.J., Chen, H., Sullivan, G. et al. High dose oral vitamin C only partially repletes low vitamin C levels in subjects with type 2 diabetes but does not improve endothelial dysfunction or insulin resistance. 64th Sci Sess Am Diabetes Assoc (June 4-8, 2004, Orlando, Florida): Abst 13-LB.